| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Baynes Roy D. serves as a Director at ATRA and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 0 buys and 22 sells. Those positions are worth an estimated $2.1M at current prices.
Historically, Baynes Roy D.'s trades have earned a below-average insider score of 37/100 across 5 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -39.1%.
The biggest single holding is TVTX (~$2.1M) as Director. The recent filings there lean toward selling, a net 87,500 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | TVTX Travere Therapeutics, Inc. | Director | Sale+OE10b5-1 | 4,500 | $50.00 | $225,000.00 | -9.8% | +29.7% | - | |
| May 5, 2026 | TVTX Travere Therapeutics, Inc. | Director | Sale+OE10b5-1 | 4,500 | $46.65 | $209,925.00 | -10.7% | +22.7% | - | |
| May 1, 2026 | TVTX Travere Therapeutics, Inc. | Director | Sale+OE10b5-1 | 9,750 | $44.22 | $431,145.00 | -20.6% | +29.8% | - | |
| Apr 14, 2026 | TVTX Travere Therapeutics, Inc. | Director | Sale+OE10b5-1 | 32,750 | $41.29 | $1,352,130.00 | -46.6% | +33.6% | - | |
| Apr 6, 2026 | TVTX Travere Therapeutics, Inc. | Director | Sale+OE10b5-1 | 10,000 | $33.00 | $330,000.00 | -21.1% | +80.6% | - | |
| Nov 20, 2025 | NTRA Natera, Inc. | Director | Sale+OE10b5-1 | 12,780 | $219.85 | $2,809,688.61 | -41.0% | -4.4% | - | |
| Feb 6, 2025 | TVTX Travere Therapeutics, Inc. | Director | Sale+OE10b5-1 | 10,000 | $22.00 | $220,000.00 | -24.4% | -7.5% | +35.9% | |
| Jan 23, 2025 | TVTX Travere Therapeutics, Inc. | Director | Sale+OE10b5-1 | 16,000 | $20.00 | $320,000.00 | -34.0% | -19.8% | +41.5% | |
| Nov 15, 2024 | NTRA Natera, Inc. | Director | Sale+OE10b5-1 | 37,230 | $146.11 | $5,439,564.61 | -70.2% | +16.9% | +39.9% |